ASH 2020 | CAEL-101: a monoclonal antibody therapy for AL amyloidosis
Jason Valent, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the results of the Phase II CAEL101-203 study (NCT04304144) investigating the safety, tolerability and efficacy of CAEL-101 in combination with cyclophosphamide plus bortezomib and dexamethasone for immunoglobin light chain (AL) amyloidosis patients. CAEL-101 is an AL amyloid fibril reactive IgG1 monoclonal antibody with potential for therapeutic immune clearance of AL amyloid deposits from affected organs. The treatment had an impressive safety profile and showed a clear ability to improve organ function in the patients. An additional investigation was presented at ASH 2020 that analyzed CAEL-101 tolerability and pharmacokinetic profile at each dose level. 1000mg/m^2 was determined as the recommended dose for future studies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Teaching and speaking: Celgene corporation, Takeda pharmaceuticals, Amgen corporation
